Quantification of trace ²²⁷Ac and other radionuclidic impurities in mass-separated ²²⁵Ac samples produced at CERN-MEDICIS.

ABSTRACT: 225Ac is a promising candidate medical radionuclide for targeted alpha therapy of advanced stage cancers. One of the main production pathways is the high-energy proton spallation of thorium-based targets, that requires an efficient, nuclide-selective separation method to recover 225Ac from hundreds of co-produced spallation and fission products. The main radioactive contaminant of concern is 227Ac  (T1/2 = 21.8 years), that could preclude extensive medical use if not significantly suppressed. In this work, 225Ac samples were produced by mass separation of radioactive ion beams extracted from proton-irradiated thorium-based targets. The activity of 225Ac and other possible contaminants of the samples were measured using complementary gamma- and alpha-decay spectrometry methods, while 227Ac

SUBMITTER: Johnson JD 

PROVIDER: S-EPMC12222749 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature